Steroids have an important role

被引:20
作者
Bedlack, RS [1 ]
Sanders, DB [1 ]
机构
[1] Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA
关键词
D O I
10.1002/mus.1221
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The natural history of MG demonstrates that most patients need treatment beyond cholinesterase inhibitors. Thymectomy is not appropriate for all patients and often results in partial or delayed improvement that requires long-term immunosuppression. PE and IVIg are too expensive for long-term management. Azathioprine and cyclosporine have not been shown to be more efficacious than steroids, have potential side effects that are as serious as those of steroids, and are considerably more expensive. Other immunosuppressives appear promising, but are early in their development. Thus, steroids remain an important part of MG management. The lack of standardized outcome measures and direct comparison studies make it difficult to determine the "best" treatment for MG. Attention has recently been directed toward developing disease-specific outcome measures11 that should facilitate comparisons of future cohorts and promote head-to-head clinical trials.
引用
收藏
页码:117 / 121
页数:5
相关论文
共 12 条
[1]   Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis [J].
Bromberg, MB ;
Wald, JJ ;
Forshew, DA ;
Feldman, EL ;
Albers, JW .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1997, 150 (01) :59-62
[2]   Retrospective analysis of the use of cyclosporine in myasthenia gravis [J].
Ciafaloni, E ;
Nikhar, NK ;
Massey, JM ;
Sanders, DB .
NEUROLOGY, 2000, 55 (03) :448-450
[3]   Mycophenolate mofetil for myasthenia gravis: An open-label pilot study [J].
Ciafaloni, E ;
Massey, JM ;
Tucker-Lipscomb, B ;
Sanders, DB .
NEUROLOGY, 2001, 56 (01) :97-99
[4]   Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis [J].
Gajdos, P ;
Chevret, S ;
Clair, B ;
Tranchant, C ;
Chastang, C .
ANNALS OF NEUROLOGY, 1997, 41 (06) :789-796
[5]  
GAJDOS P, 1993, J NEUROL NEUROSUR PS, V56, P1157
[6]   Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology [J].
Gronseth, GS ;
Barohn, RJ .
NEUROLOGY, 2000, 55 (01) :7-15
[7]   Myasthenia gravis - Recommendations for clinical research standards [J].
Jaretzki, A ;
Barohn, RJ ;
Ernstoff, RM ;
Kaminski, HJ ;
Keesey, JC ;
Penn, AS ;
Sanders, DB .
NEUROLOGY, 2000, 55 (01) :16-23
[9]   STUDIES IN MYASTHENIA GRAVIS - REVIEW OF 282 CASES AT THE-MOUNT-SINAI-HOSPITAL, NEW YORK CITY [J].
OSSERMAN, KE ;
KORNFELD, P ;
COHEN, E ;
GENKINS, G ;
MENDELOW, H ;
GOLDBERG, H ;
WINDSLEY, H ;
KAPLAN, LI .
ARCHIVES OF INTERNAL MEDICINE, 1958, 102 (01) :72-81
[10]  
PASCUZZI RM, 1984, ANN NEUROL, V290, P81